Background: Oxidation of lipoproteins generates multiple bioactive oxidized lipids that affect atherothrombosis and endothelial dysfunction, but direct evidence of their role during therapeutic procedures is lacking. Liberated oxidized lipids may result in no-reflow phenomenon, myocardial infarction and stroke. To assess whether oxidized vasoactive lipids are released downstream from atherosclerotic plaques following percutaneous coronary and peripheral interventions we undertook a lipidomic analysis of material recovered from distal embolic protection devices from different vascular beds. Methods: The presence of specific oxidized lipids was assessed in embolized material captured by distal embolic protection devices during saphenous vein graft, carotid, renal, and superficial femoral artery interventions. Following lipid extraction, specific oxidized phospholipids (OxPL) and cholesterol esters (OxCE) were quantified in 12 filters using liquid chromatography, tandem mass spectrometry. Results: Phosphatidylcholine (PC) containing OxPL, including 1-palmitoyl-2-(5oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), C9 aldehyde PC, E2 and F2 isoprostane PC, and hydroperoxy PC were identified in the extracted lipid portion. The major oxidized PC by mass was the C9 aldehyde PC, representing 38% of all oxidized PL. Several species of OxCE, such as aldehyde, hydroperoxide, oxide and epoxy cholesterol ester derivatives from cholesteryl linoleate and cholesteryl arachidonate, were also present. The pattern of OxPL and OxCE within filters correlated well with molecules found in various forms of oxidized LDL and did not differ significantly in different vascular beds. The presence of OxPL was also confirmed using ELISA and immunohistochemistry. Conclusions: This is the first documentation of the presence and direct release of oxidized lipids from atherosclerotic plaques during percutaneous interventions from multiple vascular beds in humans. The release of such oxidized lipids into the microcirculation may mediate some of the adverse clinical outcomes that result during these intravascular interventions.
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H. Boden 1 , Matthijs Velders 1 , B.L. van der Hoeven 1 , M.J. Schalij 1 1 Leiden University Medical Center, Leiden, Netherlands Background: Recent advances in antithrombotic therapy for STEMI are accompanied by an increased risk of bleeding. So far, the CRUSADE score for bleeding risk has only been validated in NSTEMI. Methods: The risk of in-hospital major CRUSADE bleeding and 1-year mortality after primary PCI for STEMI was studied in consecutive patients who received upfront abciximab, periprocedural heparin and loading doses of aspirin and clopidogrel. Results: In total, 965 STEMI patients (61Ϯ12 yrs, 76% men) were stratified according to the CRUSADE bleeding risk score (Table) . Median CRUSADE score was 21 (14-29). Bleeding was common (21%) ranging from 11% in the very low risk group up to 69% in the very high risk group. Most common bleeding site was the femoral access site. In 3 patients, bleeding most likely led to death. Survival analysis demonstrated 1-year mortality rates of 9.2% in bleeders vs. 2.5% in non-bleeders (pϽ0.001, Figure) . Assessment of the CRUSADE risk score by ROC curve resulted in an area under the curve of only 0.68 (0.64-0.73, pϽ0.001). 
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